Skip to main content Help with accessibility Skip to main navigation

September 2023 updates to the website

The website has now been updated following September's LSCMMG

The following guidelines have been added/updated:

Gout guideline - updated

Erectile dysfunction guideline - updated

Melatonin Pathway (Children) - added

Lithium shared care guideline - updated

COPD desktop guideline - Update to follow in October

The following medicines have been updated:

Eluxadoline - Treating irritable bowel syndrome with diarrhoea (NICE TA471): removed from website

Rimegepant - Preventing migraine (NICE TA906)

The following Items will be updated and added to the website following the next Commissioning Resource Group (CRG) Meeting:

Brimonidine Tartrate (Mirvaso) 3mg/g Gel - symptomatic treatment of moderate to severe facial erythema of rosacea in adult patients

Ibandronic acid 50 mg Tablets - adjuvant treatment of early breast cancer in postmenopausal women with a high risk of recurrence (unlicensed indication)

Flupentixol (as dihydrochloride) - schizophrenia and other psychoses

Sodium fluoride 1.1%toothpaste (Duraphat) - For use by patients suffering head and neck cancer patients who have had surgery, radiotherapy and/or chemotherapy.

Bempedoic acid with ezetimibe - for treating primary hypercholesterolaemia or mixed dyslipidaemia (RAG review)

Cenobamate - treating focal onset seizures in epilepsy (NICE TA753) (RAG review)